STABILISATION MEASURES TAKEN AND END OF STABILISATION PERIOD

NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

This announcement does not constitute an offering circular and nothing herein contains an offering of securities.

With reference to the company announcement no. 7/2017 dated November 16, 2017 regarding the beginning of the stabilisation period following the initial public offering and admission to trading and official listing of the temporary purchase certificates and the shares of Orphazyme A/S (“Orphazyme”) on Nasdaq Copenhagen (the “Offering” or the “IPO”), Orphazyme has received notification that Danske Bank, acting as stabilising manager in the Offering, has taken stabilisation measures between December 6, 2017 and December 14, 2017 as set out in the attached notification with respect to the shares of Orphazyme.

Further Orphazyme has been informed by Danske Bank that the stabilisation period has ended. During the stabilisation period stabilisation transactions has been carried out in the temporary purchase certificates and the shares of Orphazyme. Reference is made to the attached notification. No further stabilisation transactions will take place.

Danske Bank has thereby informed Orphazyme that it will not exercise its overallotment option as described in the prospectus published by Orphazyme A/S on November 6, 2017 and accordingly no new shares will be issued in this regard. The 1,125,000 shares in Orphazyme previously delivered to Danske Bank pursuant to a stock lending agreement will be returned to Novo Holdings A/S as also set out in company announcement no. 5/2017 dated November 16, 2017 regarding the result and pricing of the IPO.

https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=3414011&lang=en-GB&companycode=dk-orpha&v=

 

For additional information, please contact

Orphazyme

Anders Vadsholt, CFO                                                         +45 28 98 90 55